Cytosurge and Lexogen have entered into a partnership, a sequence of lives they can use

Follow the order of the Zellbiopsy probes

ZURICH, Switzerland and WIEN, Österreich, October 16, 2024 (GLOBE NEWSWIRE) — Cytosurge AG, an electronic manipulation company and Lexogen, a pioneer in the field of RNA sequencing, have made possible their partnership, one that Sequenzierung von lebenden Zellen (Live-seq) voranzutreiben. I am a member of the FluidFM section^® OMNIUM platform ^von Cytosurge with Lexogen’s LUTHOR HD Kit integrates an optimized workflow, supporting cell life and life cycle sequence for smoother and smoother power. Our more Einzelheiten zu erhalten, beladen Sie de gemeinsamen Anwendungshinweis herunter.

Live-seq is a fast technology, which works at the ETH Zurich and the EPFL in Switzerland and the order of the transcriptions a Zelle-ermöglicht, with the Zelle in Leben bleibt. There are a number of paradigms that have developed herkömmliche methods, while they could carry out the research and provide new possibilities for dynamic, time-consuming transcryptomic studies. That FluidFM^®-Cytosurge technology allows for a clean extraction of Zytoplasma biopsy probes, which can also be damaged. Extremely small RNA mixtures (typically 1 pg) can be found in small Biopsy probes with a large sample of RNA-Seq-Bibliotheksvorbereitung. Here you can see the LUTHOR HD Kit from Lexogen. LUTHOR weist Tausende von Genes in RNA-Mengen von nur 0.15 pg nach – was weit unter dem-RNA-Gehalt a Zelle lies – and is damn ideal for Live-seq.

The fortification on the way to caliber bars and umfassenden Live-seq-losungen vorantreiben

The partnership is working on a number of scalar bars, user-friendly workflow for live-seq preparations, which can be analyzed efficiently, the transkriptome single cells in the fresh air of the day to analyze, changes in gene expression in the life of the cells, and the natural process of processing, and The possible exposure to the disease in the Zellbiologie and the therapeutic Entwicklung führen kan.

“The Partnership with Lexogen is a separated Schritt, a separate Mission, a price-Single analysis of ermöglichen, voranzutreiben,” said Pascal Behr, Ph.D., CEO of Cytosurge. “The Combination offers FluidFM^®-Technology with the high research library of Lexogen ermöglicht is one, an end-to-end solution for live-seq, that new path in the transkriptomforschung isoffnet.”

Lexogen’s LUTHOR HD technology is now available for THOR^®-Amplification and adjustment through a very simple operation with minimal RNA input. In combination with FluidFM with a study of RNA-containing biopsy probes from living organisms, complex complex processes can be carried out with one of the disinterested analyses. “These partners are open to new possibilities, so that they can be followed by changes in their own environment, especially in the development of the development process, including subtle changes in the population and their growth potential,” says Filippo Passardi, Ph.D., Product Manager at Lexogen.

Cytosurge and Lexogen can cause the most common problems generated with LUTHOR HD high transcryption rates from biopsy probes performed with the FluidFM^®-OMNIUM platform were won. “Diese Partnerschaft is no longer an Angebot, which has the potential to bring about a revolution,” very much like Dario Ossola, Ph.D., Product Manager at Cytosurge.

Skilled Entwicklungen

The merging will be done through the analysis of other types and the rendering of the live-seq workflows using more time-driven configurations. Both solutions are best, this technology can produce a publication suitable for machines and labor around the world, one of the most likely problems with power supply.

Uber Cytosurge

Cytosurge AG has deployed innovative solutions under the FluidFM version^®-Technology for the single manipulation. This platform combines microfluidic and Kraftrückkoplung and ermöglicht so fine Zellinteractionen that the Verständnis zellulärer processes improve. With over 120 FluidFM weltweit installations^®-Systems are Cytosurge flight in the Einzelzellforschung.

Uber Lexogen

Lexogen is an innovative solution in RNA sequencing and offers innovative solutions for transcryption research. Seine products come from the Anforderungen der Wisschaftlichen Gemeinschaft-zugeschnitten and beet End-to-End-Losungen, which high quality and very good care. More information can be found on the Cytosurge and Lexogen websites.

Contact us

Cytosurge AG
Sabina Packeiser, PhD, Head of Marketing
Phone +41 43 544 87 00
E-mail (email protected)

Lexogen
Amra Dedic
Brand and events manager
Phone +43 660 69 66 045
E-mail (email protected)

Quelle Hugin